Xizang Haisco Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

• ▼

  Tax bureau flags false invoices at Haisco subsidiary A tax bureau named a Haisco holding subsidiary among five drugmakers that received fake VAT invoices worth 1.26 million yuan from a now-deregistered vendor. The amount is small, but it raises compliance and possible penalty risk, a modest drag on the shares.

  It is the only clearly negative regulatory event in the period and a real counterweight to the good news.

• ▲

  Interim profit of 851 million yuan on 3.1 billion revenue Haisco's first-half 2026 report showed revenue of 3.096 billion yuan and net profit of 851 million yuan, with strong cash flow and a 17.68% return on equity. Solid earnings and a healthy balance sheet support the stock's value.

  The interim results are the core fundamental update that tells readers how the business is actually performing.

• ▲

  New drug approvals and partner trial success lift pipeline Haisco's HSK60002 tablet won Chinese clinical trial approval for inflammatory disease, and partner AirNexis said AN01 met its main goal in a China Phase 2b COPD study run by Haisco. Both validate the pipeline and raise hopes for future revenue.

  These are the period's main technology catalysts that can drive long-term growth expectations.

• ▲

  Dividend and subsidiary funding show cash confidence Haisco plans to pay 5.26 yuan per 10 shares, about 600 million yuan, and will lend up to 261 million yuan to its new biotech subsidiary for ADC and CAR-T research. Returning cash while funding growth signals confidence in its finances.

  The payout and internal funding show management's confidence and support shareholder returns, a positive capital signal.

Based on 6 stories →

• ▲

  First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.

  This is the core earnings catalyst that directly explains the stock's positive momentum.

• ▲

  New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.

  This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.

• ▲

  New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.

  This is a fresh, material deal that directly adds near-term cash and potential long-term value.

• ▲

  Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.

  It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

Based on 6 stories →

• ▲

  Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

  This is the core financial result that directly shows improved profitability and validates the growth strategy.

• ▲

  Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

  These regulatory milestones are new and directly add to the company's growth prospects.

• ▲

  Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

  This is a new major business development deal that highlights the value of its innovative pipeline.

Based on 6 stories →